Positive interim results for Agios Pharmaceuticals

Agios Pharmaceuticals Inc. (Nasdaq: AGIO) reported positive interim data from a Phase 1 study of AG-120 in treating patients with acute myeloid leukemia.Shares of the biopharmaceutical leaped $12.16 to close at $95.97.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.